212 related articles for article (PubMed ID: 32964819)
1. Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates.
Poitras EL; Gust SL; Kerr PM; Plane F
Curr Med Chem; 2021; 28(12):2418-2437. PubMed ID: 32964819
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
[TBL] [Abstract][Full Text] [Related]
3. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.
Lewis GD; Semigran MJ
Curr Heart Fail Rep; 2004 Dec; 1(4):183-9. PubMed ID: 16036043
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
5. Decreased Cyclic Guanosine Monophosphate-Protein Kinase G Signaling Impairs Angiogenesis in a Lamb Model of Persistent Pulmonary Hypertension of the Newborn.
Sharma M; Rana U; Joshi C; Michalkiewicz T; Afolayan A; Parchur A; Joshi A; Teng RJ; Konduri GG
Am J Respir Cell Mol Biol; 2021 Nov; 65(5):555-567. PubMed ID: 34185619
[TBL] [Abstract][Full Text] [Related]
6. Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders.
Samidurai A; Xi L; Das A; Kukreja RC
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():585-615. PubMed ID: 36206989
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Multifaceted Potential of Sildenafil in Medicine.
Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
Corbin JD; Francis SH; Webb DJ
Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
[TBL] [Abstract][Full Text] [Related]
12. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Wilkins MR; Wharton J; Grimminger F; Ghofrani HA
Eur Respir J; 2008 Jul; 32(1):198-209. PubMed ID: 18591337
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.
Deruelle P; Grover TR; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2005 Nov; 289(5):L798-806. PubMed ID: 15964898
[TBL] [Abstract][Full Text] [Related]
15. [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension].
Beltrán-Gámez ME; Sandoval-Zárate J; Pulido T
Arch Cardiol Mex; 2015; 85(3):215-24. PubMed ID: 26047999
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels.
Gómez-Vallejo V; Ugarte A; García-Barroso C; Cuadrado-Tejedor M; Szczupak B; Dopeso-Reyes IG; Lanciego JL; García-Osta A; Llop J; Oyarzabal J; Franco R
J Neurochem; 2016 Jan; 136(2):403-15. PubMed ID: 26641206
[TBL] [Abstract][Full Text] [Related]
17. Aberrant cGMP signaling persists during recovery in mice with oxygen-induced pulmonary hypertension.
Perez M; Lee KJ; Cardona HJ; Taylor JM; Robbins ME; Waypa GB; Berkelhamer SK; Farrow KN
PLoS One; 2017; 12(8):e0180957. PubMed ID: 28792962
[TBL] [Abstract][Full Text] [Related]
18. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Turko IV; Ballard SA; Francis SH; Corbin JD
Mol Pharmacol; 1999 Jul; 56(1):124-30. PubMed ID: 10385692
[TBL] [Abstract][Full Text] [Related]
20. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
